International Patent Filed for Ultra-Long-Acting Platform
Extending Drug Efficacy by Combining Multiple Active Molecules
Animal Studies Confirm Suppression of Weight Regain After Treatment Discontinuation

Alteogen announced on the 17th that it has completed an international patent application (PCT) for its ultra-long-acting platform technology, the 'long-acting conjugate,' which combines multiple active molecules to extend the duration of drug efficacy.


Alteogen Headquarters Exterior. Alteogen

Alteogen Headquarters Exterior. Alteogen

View original image

This technology advances existing platforms that selectively conjugate drugs to specific sites of antibodies. It enables the implementation of multiple active molecules into a single conjugate to prolong a drug's half-life. The company explained that this approach can reduce dosing frequency and extend dosing intervals, making it applicable to the development of long-acting therapeutics.


Alteogen is currently developing 'ALT-M5,' a candidate for obesity treatment that can be administered once a month by applying this platform. Animal studies have confirmed both the possibility of once-monthly dosing with ALT-M5 and its ability to suppress weight regain (rebound) after discontinuation. Detailed results are scheduled to be released at a scientific conference.


The research findings will be presented at 'ObesityWeek 2026,' the annual meeting of The Obesity Society in the United States, which will be held November 14-17 in Washington, D.C. The study covers the effectiveness of a once-monthly injectable incretin fusion protein in suppressing weight regain.



Taeyeon Jeon, CEO of Alteogen, stated, "The technology for which we have filed a patent is a platform applicable to various biopharmaceuticals, enabling the development of long-acting, once-monthly dosing formulations. Based on the results from ALT-M5 animal studies, we plan to develop a differentiated obesity treatment that meets unmet needs by enabling once-monthly administration and suppressing weight regain after discontinuation."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing